期刊文献+

进行性骨化性纤维发育不良的临床特点及诊治

Clinical Features,Diagnosis and Management of Fibrodysplasia Ossificans Progressiva
下载PDF
导出
摘要 进行性骨化性纤维发育不良(FOP)是一类罕见的以进行性的异位骨化为特点的先天性疾病。该病造成患者严重运动障碍,同时累及全身多系统。其发病率相对低,临床医师对FOP的认识不完全,导致误行有创操作或手术治疗,造成异位骨化进展。为增强对疾病的认识,本文就FOP的流行病学、病理机制、临床特征及诊断与治疗进行综述。 Fibrodysplasia ossificans progressiva(FOP)is a rare congenital disease characterized by progressive heterotopic ossification,causing severe immobility with multi-system involvement.The relatively low incidence rate and incomplete knowledge among clinicians of the disease often result in misuse of invasive pro-cedures or surgical treatment,leading to the progression of heterotopic ossification.To promote the knowledge of FOP,this article presents a comprehensive review involving epidemiology,pathological mechanisms,clinical features,diagnosis,and management of the FOP.
作者 赵俊铎 沈建雄 ZHAO Junduo;SHEN Jianxiong(Department of Orthopaedic Surgery,Beijing Key Laboratory for Genetic Research of Skeletal Deformity,Key Laboratory of Big Data for Spinal Deformities,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处 《罕见病研究》 2023年第4期501-508,共8页 Journal of Rare Diseases
关键词 进行性骨化性纤维发育不良 异位骨化 罕见病 fibrodysplasia ossificans progressiva heterotopic ossification rare diseases
  • 相关文献

参考文献1

二级参考文献19

  • 1Kaplan FS, Glaser DL, Shore EM, et al. The phenotype of fibrodysplasia ossificans progressiva [J]. Clin Rev Bone Miner Metab,2005,3 (3-4) : 183-188.
  • 2Kaplan FS, Xu M, Seemann P, et 01. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotype are caused by mutation in the bone morphognetic protein (BMP) type I receptor ACVR1 [J]. Hum Muta,2009,30 (3) : 379-390.
  • 3Zaghloul KA, Heuer GG, Guttenberg MD, et ol. Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva [J]. J Neursurg Pediatrics, 2008,1 ( 1 ) : 91-94.
  • 4Ahmed SF, Barr DG, Bonthron DT. GNAS1 Mutations and progressive osseous heteroplasia [J]. N Engl J Med,2002, 346(2) :99-106.
  • 5Pignolo R J, Suda RK, Kaplan FS. The fibrodysplasia ossificans progressiva lesion [J]. Clin Rev Bone Miner M etab, 2005,3 (3-4) : 195-200.
  • 6Kaplan FS, Shore EM, Glaser DL, et al. The medical management of fibrodysplasia ossificans progressive: current treatment considerations [J]. Clin Proc Intl Consort FOP, 2005,1 (3) : 1-71.
  • 7Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing [ J ]. Nat Med, 1999,5 (12) : 1418-1423.
  • 8Simmons FER. Advances in HI-antihistamines [J]. N Engl J Med,2004,351 (21) :2203-2217.
  • 9Rath B, Nam J, Deschner J, et al. Biomechanical forces exert anabolic effects on osteoblasts by activation of SMAD 1/5/8 through type 1 BMP receptor [J]. Biorheology,2011, 48(1) :37-48.
  • 10Ahschuler EL. Consideration of Rituximab for fibrodysplasia ossificans progressiva [J]. Med Hypotheses. 2004,63 (3) : 407-408.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部